UK biotech funding is having a strange year: the headline numbers look stronger than they feel on the ground.
Life sciences investment rebounded sharply in 2024, yet venture capital pulled back through 2025, leaving founders raising today to navigate a market that's more selective, more concentrated, and more reliant on overseas capital than it was two years ago.
Why UK Biotech Funding Is Tightening
UK biotech funding tightened back through 2025, with venture capital falling 13.2% year-on-year to £1.79 billion across just 58 deals even after a strong rebound the year before. That rebound was real: life sciences FDI hit £2.1 billion in 2024, a 164% jump on 2023, pushing the UK to fourth among 18 comparator countries, while life sciences equity finance overall climbed to £4.5 billion, up 32% (GOV.UK, Office for Life Sciences).
Two Q1 megadeals Isomorphic Labs and Verdiva Bio accounted for nearly 47% of the entire year's venture capital, according to the BioIndustry Association (BIA), masking a market actually starved for mid-sized scale-up rounds. Public markets fared worse: 2025 marked a third straight year without a single UK biotech IPO, and follow-on financing collapsed 93.6% to £95.8 million.
There are green shoots, though. Q1 2026 brought £516 million in UK biotech venture capital, up 17% quarter-on-quarter, with deal count rising 60% to 24 transactions (BIA). The structural issue underneath it all is domestic capital depth: overseas institutions made up 68% of Series A investors and 89% of Series B+ investors in UK deals in 2025. Science isn't the problem. The pool of UK money willing to back it at scale still is.
Grant vs Equity Funding
Grant funding gives UK biotech startups up to £2 million in non-dilutive capital through Innovate UK's Biomedical Catalyst, while equity funding trades ownership for faster-moving, larger sums from venture investors. The Biomedical Catalyst runs two strands: up to £500,000 for early-stage R&D over 6–24 months, and £500,000–£2 million for larger projects over 6–36 months, covering up to 70% of costs for small companies (60% medium, 50% large). Success rates sit around 10%, so this isn't a fallback it needs a dedicated application effort.
Equity remains the dominant route for scaling, but the UK gap is well documented: British Business Bank analysis shows UK companies receive roughly half the venture capital their US counterparts do(According to the British Business Bank).
Under the 2023 Mansion House Compact, pension signatories committed 5% of assets to unlisted companies by 2030; the May 2025 Mansion House Accord doubled that to 10% into private markets, half UK-directed. The British Growth Partnership Fund reached a £200 million first close in November 2025 with Aegon UK, NatWest Cushon and M&G on board real capital, finally moving, though BIA has called progress "too slow" for life sciences investment specifically.
MHRA Fast-Track and What It Means for Investors
The MHRA's Innovative Licensing and Access Pathway (ILAP) fast-tracks medicines by coordinating early engagement between the regulator, NICE and the NHS through a single Innovation Passport application.
ILAP relaunched on 30 January 2025 after criticism that the original scheme's entry criteria were too permissive to be sustainable. The new version runs on quarterly cycles, charges a non-refundable £3,624 fee, and has visibly tightened the bar: only three Innovation Passports were awarded across all of 2025, and one assessment round produced zero awards.
That's the signal worth reading for investors, ILAP designation is now a genuine selectivity marker, not the loosely awarded badge it was pre-relaunch. Holders gain access to a potential 150-day accelerated Marketing Authorisation Application assessment and rolling review, both of which shorten the runway between clinical progress and commercial return.
Milestone-Based Investment Explained
Milestone-based investment releases venture capital in tranches, with each payment triggered only once a biotech company hits an agreed clinical or scientific milestone rather than handing over the full round upfront. It's especially common in biotech venture capital because it maps naturally onto the cost structure of drug development.
For investors, staged capital creates what's essentially an option: continue funding a venture that's working, walk away from one that isn't, or expand backing when results beat expectations. This is now common enough that the National Venture Capital Association built tranche mechanics into its model stock purchase agreement in October 2025. For founders, hitting milestones typically unlocks the next tranche at a higher valuation, meaning less dilution overall but missed milestones can strain the runway fast.
Most Active UK Biotech VCs
Sofinnova Partners has ranked among the UK's most active biotech venture capital investors in both 2022 and 2023, per BIA data, sharing that title with UK firms Meltwind Advisory and o2h Ventures in 2023, and appearing again in 2022 alongside Oxford Science Enterprises and Dutch firm Forbion.
In 2023, Sofinnova and Pfizer Ventures were also the most active non-UK investors by participation, involved in deals totalling £164 million and £88 million respectively.
Beyond those named leaders, a consistent group anchors UK-focused life sciences investment: Syncona, the FTSE250-listed investor behind Autolus and Freeline; SV Health Investors, which has backed over 200 companies across three decades; Cambridge Innovation Capital; and government-backed British Patient Capital, which has invested in 44 companies since 2018.
Advent Life Sciences and Epidarex Capital round out the group of investors founders chasing UK biotech funding are most likely to encounter.
What Founders Should Prepare For
UK biotech startups raising in early 2026 should expect international capital to dominate anything beyond seed stage, with overseas institutions making up 68% of Series A investors and 89% of Series B+ investors (BIA, Q1 2026). Founders should assume their data room will be reviewed primarily by non-UK teams, and pitch accordingly.
Capital is also concentrated, skewed toward fewer, larger rounds. Founders eyeing ILAP should build the quarterly cycle and £3,624 fee into their regulatory timeline. And anyone treating the Biomedical Catalyst as a backup plan should reconsider a roughly 10% success rate means it needs the same rigour as a proper funding round.
The Bottom Line
UK biotech funding in 2026 rewards founders who plan for a leaner, more international, more evidence-driven market. Grants still matter for early R&D, ILAP is now a genuine selectivity signal rather than a rubber stamp, and milestone-based structures are becoming the venture-side norm. The startups raising well this year treat overseas investors, staged capital and regulatory timelines as the default, not the exception.
FAQ
1. How do UK biotech startups raise funding?
UK biotech startups typically combine non-dilutive grants, such as Innovate UK's Biomedical Catalyst (up to £2 million), with venture capital rounds increasingly led by overseas investors — 68% of Series A and 89% of Series B+ investors in UK deals in 2025 (BIA).
2. What is milestone-based investment in biotech?
Milestone-based investment releases venture capital in tranches, unlocking each payment only once a biotech company hits an agreed clinical or scientific milestone. It reduces investor risk while letting founders raise later tranches at a higher valuation.
3. Which UK VCs invest in life sciences?
Leading UK-focused investors include Syncona, SV Health Investors, Cambridge Innovation Capital, Oxford Science Enterprises and British Patient Capital, alongside biotech venture capital firms such as Sofinnova Partners.
Also Read: Startup Term Sheet Checklist: 5 Questions to Ask First
Sources: GOV.UK's Office for Life Sciences, the BioIndustry Association's UK Biotech Financing reports (2022–2026), the MHRA, British Business Bank, and British Patient Capital.
The EP+ Editorial Desk covers UK startups, founder stories, and venture capital.
